Antitumour Activity of Dehydroxymethylepoxyquinomycin (DHMEQ): a Literature Review
Carcinogenesis research uncovers new pathogenesis links as vulnerable targets of effective antitumour therapies. Among the key mediators of immune response, cell proliferation, cell apoptosis and inflammation is transcription factor NF-κB. Misregulation of an NF-κB-dependent pathway is found in soli...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bashkir State Medical University
2021-04-01
|
| Series: | Креативная хирургия и онкология |
| Subjects: | |
| Online Access: | https://www.surgonco.ru/jour/article/view/572 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839584534246457344 |
|---|---|
| author | K. Umezawa Sh. Kh. Gantsev Sh. R. Kzyrgalin R. S. Yamidanov R. A. Amirov E. I. Zhuk |
| author_facet | K. Umezawa Sh. Kh. Gantsev Sh. R. Kzyrgalin R. S. Yamidanov R. A. Amirov E. I. Zhuk |
| author_sort | K. Umezawa |
| collection | DOAJ |
| description | Carcinogenesis research uncovers new pathogenesis links as vulnerable targets of effective antitumour therapies. Among the key mediators of immune response, cell proliferation, cell apoptosis and inflammation is transcription factor NF-κB. Misregulation of an NF-κB-dependent pathway is found in solid and haematopoietic tumour cells. One of the best known NF-κB functions is expression regulation of genes involved in the apoptosis inhibition or activation and survival in both intact and malignant cells. The NF-κB-mediated pathways’ involvement in carcinogenesis, angiogenesis and tumour resistance to chemo- and radiotherapies makes this factor a promising target for drug anti-cancer interventions. This review summarises evidence on the antitumour and anti-inflammatory activity of a high-potent and specific low molecular-weight NF-κB inhibitor, dehydroxymethylhepoxyquinomycin (DHMEQ), as a candidate therapeutic agent in treatment for variant malignancies. |
| format | Article |
| id | doaj-art-ac225ac206c74c6687b51d44d931fa18 |
| institution | Matheson Library |
| issn | 2076-3093 2307-0501 |
| language | English |
| publishDate | 2021-04-01 |
| publisher | Bashkir State Medical University |
| record_format | Article |
| series | Креативная хирургия и онкология |
| spelling | doaj-art-ac225ac206c74c6687b51d44d931fa182025-08-03T19:48:54ZengBashkir State Medical UniversityКреативная хирургия и онкология2076-30932307-05012021-04-01111687510.24060/2076-3093-2021-11-1-68-75419Antitumour Activity of Dehydroxymethylepoxyquinomycin (DHMEQ): a Literature ReviewK. Umezawa0Sh. Kh. Gantsev1Sh. R. Kzyrgalin2R. S. Yamidanov3R. A. Amirov4E. I. Zhuk5Centre of Personified Oncology of the Academy of Sciences of the Republic of BashkortostanBashkir State Medical University; Centre of Personified Oncology of the Academy of Sciences of the Republic of BashkortostanBashkir State Medical University; Centre of Personified Oncology of the Academy of Sciences of the Republic of BashkortostanCentre of Personified Oncology of the Academy of Sciences of the Republic of BashkortostanCentre of Personified Oncology of the Academy of Sciences of the Republic of BashkortostanBashkir State Medical UniversityCarcinogenesis research uncovers new pathogenesis links as vulnerable targets of effective antitumour therapies. Among the key mediators of immune response, cell proliferation, cell apoptosis and inflammation is transcription factor NF-κB. Misregulation of an NF-κB-dependent pathway is found in solid and haematopoietic tumour cells. One of the best known NF-κB functions is expression regulation of genes involved in the apoptosis inhibition or activation and survival in both intact and malignant cells. The NF-κB-mediated pathways’ involvement in carcinogenesis, angiogenesis and tumour resistance to chemo- and radiotherapies makes this factor a promising target for drug anti-cancer interventions. This review summarises evidence on the antitumour and anti-inflammatory activity of a high-potent and specific low molecular-weight NF-κB inhibitor, dehydroxymethylhepoxyquinomycin (DHMEQ), as a candidate therapeutic agent in treatment for variant malignancies.https://www.surgonco.ru/jour/article/view/572dehydroxymethylepoxyquinomycindhmeqantitumour activitynf-kappa bcarcinogenesisovarian cancerbreast cancerprostate cancer |
| spellingShingle | K. Umezawa Sh. Kh. Gantsev Sh. R. Kzyrgalin R. S. Yamidanov R. A. Amirov E. I. Zhuk Antitumour Activity of Dehydroxymethylepoxyquinomycin (DHMEQ): a Literature Review Креативная хирургия и онкология dehydroxymethylepoxyquinomycin dhmeq antitumour activity nf-kappa b carcinogenesis ovarian cancer breast cancer prostate cancer |
| title | Antitumour Activity of Dehydroxymethylepoxyquinomycin (DHMEQ): a Literature Review |
| title_full | Antitumour Activity of Dehydroxymethylepoxyquinomycin (DHMEQ): a Literature Review |
| title_fullStr | Antitumour Activity of Dehydroxymethylepoxyquinomycin (DHMEQ): a Literature Review |
| title_full_unstemmed | Antitumour Activity of Dehydroxymethylepoxyquinomycin (DHMEQ): a Literature Review |
| title_short | Antitumour Activity of Dehydroxymethylepoxyquinomycin (DHMEQ): a Literature Review |
| title_sort | antitumour activity of dehydroxymethylepoxyquinomycin dhmeq a literature review |
| topic | dehydroxymethylepoxyquinomycin dhmeq antitumour activity nf-kappa b carcinogenesis ovarian cancer breast cancer prostate cancer |
| url | https://www.surgonco.ru/jour/article/view/572 |
| work_keys_str_mv | AT kumezawa antitumouractivityofdehydroxymethylepoxyquinomycindhmeqaliteraturereview AT shkhgantsev antitumouractivityofdehydroxymethylepoxyquinomycindhmeqaliteraturereview AT shrkzyrgalin antitumouractivityofdehydroxymethylepoxyquinomycindhmeqaliteraturereview AT rsyamidanov antitumouractivityofdehydroxymethylepoxyquinomycindhmeqaliteraturereview AT raamirov antitumouractivityofdehydroxymethylepoxyquinomycindhmeqaliteraturereview AT eizhuk antitumouractivityofdehydroxymethylepoxyquinomycindhmeqaliteraturereview |